MedTrace Logo

Effects of Oral Salmon Calcitonin in Human Osteoarthritis

NCT00376311 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2006-09-14

No results posted yet for this study

Summary

To assess the safety, tolerability and clinical efficacy of oral salmon calcitonin in patients suffering from osteoarthritis

Conditions

Interventions

DRUG

oral salmon calcitonin

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Daniel H Manicourt, MD, PhD · Department of Rheumatology, University hospital St Luc, Brussels, Belgium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Completion
2004-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00376311 on ClinicalTrials.gov